Combination therapy before liver transplant for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial studies how well combining local treatments with targeted drugs and immunotherapy works for patients with liver cancer who are waiting for a transplant. It aims to see if this approach is safe and helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older.
- You have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC).
- Your cancer is at a stage called CNLC Stage I to IIIA (meaning it hasn't spread too far).
- Your cancer has not spread outside your liver (no extrahepatic metastasis).
- You do not have a specific type of severe blood clot in the liver (Type IV portal vein tumor thrombus).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at combining different treatments (local therapies, targeted therapy, and immunotherapy) for people with liver cancer that cannot be removed by surgery. The goal is to see how safe and effective these combinations are for a broad group of patients.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This study tests whether giving targeted therapy and immunotherapy at the same time or one after the other is better for shrinking liver tumors that can't be removed right now but might be removable after treatment.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests giving atezolizumab plus bevacizumab before liver transplant in people with hepatocellular carcinoma (HCC) that is too advanced to be listed within the “Milan criteria,” but still transplant-eligible. The goal is to control the cancer outside the transplant period and improve transplant outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.